CHLORMERODRIN HG 197
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Jun 1974
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Chlormerodrin HG 197 is a radiopharmaceutical injectable diagnostic agent approved in 1974 by Bracco. The specific indication and mechanism of action are not publicly documented in available data. This legacy product represents an early-stage nuclear medicine diagnostic modality.
LOE Approaching
With LOE approaching and no active clinical pipeline, brand team headcount and investment are likely minimal or reallocating to newer diagnostics.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings reflect this product's late-lifecycle status; career opportunities are limited to maintenance and compliance roles rather than growth or launch initiatives. Working on Chlormerodrin HG 197 would focus on portfolio management, regulatory maintenance, and potential discontinuation planning.
Product Manager (Legacy Brands)Regulatory Affairs Specialist
Worked on CHLORMERODRIN HG 197 at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.